In a finding that could reshape the search for new treatments against one of the deadliest gynecologic malignancies, researchers in Shanghai have identified the approved lung cancer drug tepotinib as a potent inhibitor of ovarian cancer growth, acting through an unexpected molecular target known as LY75. The study, published in the Journal of Ovarian Research, combines large-scale computational screening, structural biology, and preclinical testing to make a case for repurposing an existing medicine against a disease that urgently needs new options.

Ovarian cancer remains one of the most lethal cancers affecting women, largely because it is often diagnosed at an advanced stage and because resistance to platinum-based chemotherapy and PARP inhibitors eventually develops in most patients. High-grade serous ovarian cancer, the most common and aggressive subtype, has proven particularly stubborn, and survival rates have improved only marginally over recent decades. Against this backdrop, the idea of finding new uses for drugs that have already passed safety testing in humans, a strategy known as drug repurposing, has gained considerable traction. The new study demonstrates how modern computational tools can accelerate that process dramatically.

The research team, led by Yang Xiao, Wei Xia, and Yanan Song of Pudong Gongli Hospital and the Shanghai University of Medicine and Health Sciences, began by focusing on LY75, also known as CD205 or DEC205, a C-type lectin receptor best known for its role in antigen uptake by dendritic cells. Mining data from The Cancer Genome Atlas and the Human Protein Atlas, the investigators found that LY75 was significantly upregulated in ovarian cancer tissues compared with healthy tissue. More importantly, elevated LY75 expression correlated with shorter progression-free survival, marking the protein as both a potential biomarker of aggressive disease and an attractive therapeutic target.

With the target in hand, the team turned to structure-based virtual screening. Rather than testing thousands of compounds in the laboratory, they used the published crystal structure of the LY75 protein, deposited in the Protein Data Bank under the identifier 8K8H, as a template to computationally dock molecules from the TargetMol compound library. Docking predicts how well a small molecule fits into a binding pocket on a protein, but the researchers went considerably further. They applied MM/GBSA calculations, a method that estimates binding free energy by combining molecular mechanics forces with implicit solvent models, to rescore candidate poses. They also employed protein-ligand interaction fingerprints, or PLIF analysis, to compare the binding patterns of candidates against known interaction motifs, and ran ADMET predictions to filter out compounds likely to fail on absorption, metabolism, or toxicity grounds before any experiment was performed.

From this computational funnel, tepotinib emerged as the leading candidate. Tepotinib is an orally available small molecule approved in several countries for the treatment of non-small cell lung cancer harboring MET exon 14 skipping mutations, where it acts as a MET kinase inhibitor. Its appearance as a strong LY75 binder raised an obvious question: was any anti-cancer effect simply a consequence of MET inhibition? The team anticipated this concern and designed their study around it, measuring c-MET expression in their cell models, examining MET–LY75 co-expression patterns, and running parallel pharmacological controls with capmatinib, another selective MET inhibitor, to disentangle the two mechanisms.

The laboratory experiments delivered striking results. Tepotinib preferentially inhibited ovarian cancer cell lines with high LY75 expression, achieving half-maximal inhibitory concentrations, or IC₅₀ values, of 16.31 micromolar in SKOV3 cells and 18.91 micromolar in OVCAR-8 cells. In contrast, the drug showed markedly weaker activity against HO8910 cells, which express low levels of LY75, a dose-response pattern consistent with LY75 serving as the drug’s relevant target rather than an incidental one. To confirm a direct physical interaction, the researchers turned to surface plasmon resonance, a label-free optical technique that measures real-time binding between molecules immobilized on a sensor surface. The experiments confirmed that tepotinib binds LY75 directly, with a kinetic dissociation constant of 2.52 micromolar and a steady-state K_D of 3.74 micromolar, values indicating a specific and measurable interaction.

Perhaps the most intriguing mechanistic finding concerns what tepotinib does to the LY75 protein once bound. Treatment with the drug induced apoptosis in the sensitive cell lines, suppressed their migratory capacity, a process closely tied to metastatic spread, and downregulated LY75 protein levels. When the team probed how this downregulation occurred, they found that tepotinib accelerated LY75 degradation through a pathway that does not depend on the ubiquitin-proteasome system, the cell’s standard machinery for tagging unwanted proteins for destruction. Cycloheximide chase experiments, which block new protein synthesis and allow the decay rate of existing proteins to be measured, supported this conclusion. The identity of the alternative degradation route remains an open question, but the observation suggests tepotinib may engage lysosomal or autophagic pathways, a hypothesis that will require further work to confirm.

The in vivo evidence proved even more compelling. In mouse xenograft models implanted with SKOV3 ovarian cancer cells, oral administration of tepotinib markedly suppressed tumor growth, achieving a tumor inhibition rate of 79.6 percent. Analysis of the excised tumors showed reduced LY75 expression in the treated animals, consistent with the drug engaging its target in living tissue. All animal procedures were approved by the Institutional Animal Care and Use Committee of Shanghai Health Medical College and conducted in accordance with the ARRIVE guidelines for reporting animal research.

Crucially, the MET controls strengthened rather than weakened the case for LY75 as the operative target. Capmatinib, a structurally distinct MET inhibitor, failed to reproduce the full anti-tumor activity of tepotinib in the ovarian cancer models, and analyses of c-MET expression and MET–LY75 co-expression in patient datasets suggested that MET inhibition alone could not account for the magnitude of benefit observed. The authors therefore conclude that tepotinib’s effect in ovarian cancer reflects a genuine dual pharmacology, with LY75 binding and subsequent LY75 protein downregulation contributing substantially to its activity.

The implications of the study extend in several directions. First, it elevates LY75 from an immunological curiosity to a candidate therapeutic target in ovarian cancer, a protein whose abundance in tumors and association with poor prognosis make it a marker worth tracking clinically. LY75 has already attracted attention in oncology as a target for antibody-drug conjugates, given its presence on the surface of certain tumor cells and its efficient internalization, and the new findings add a small-molecule dimension to that conversation. Second, the work offers a template for computational drug repurposing: crystal-structure-guided docking, energy-based rescoring, interaction fingerprinting, and ADMET filtering followed by rigorous biochemical and in vivo validation. The approach identifies candidates in silico in a fraction of the time and cost of conventional screening campaigns.

Third, and most immediately, the results argue for clinical exploration of tepotinib in ovarian cancer, particularly in patients whose tumors express high levels of LY75. Because the drug is already approved and its safety profile in humans is documented, the path from laboratory finding to clinical trial is potentially shorter than for a de novo compound. The micromolar potencies observed in cell culture are modest by the standards of modern targeted therapy, and patients would likely require careful dosing studies, biomarker-based selection, and possibly drug combinations to translate the xenograft results into human benefit. Questions also remain about whether the ubiquitin-proteasome-independent degradation mechanism operates identically in human tumors and about the precise structural features of the tepotinib–LY75 interaction that could be optimized in next-generation analogs.

The study is not without limitations, as its authors acknowledge. The work relies on cell lines and xenografts rather than patient-derived models, and the correlation between LY75 expression and drug sensitivity, while suggestive, has been established across only a handful of cell lines. Prospective validation in patient-derived xenografts and organoids, ideally stratified by LY75 expression, would sharpen the biomarker hypothesis considerably. Nonetheless, the convergence of computational prediction, biochemical confirmation, mechanistic insight, and animal efficacy data makes this one of the more complete preclinical repurposing cases published for ovarian cancer in recent memory.

For a disease in which the therapeutic arsenal has expanded slowly and resistance is nearly universal, the prospect that a drug already sitting on pharmacy shelves could be redirected against a newly validated molecular target is the kind of story that resonates far beyond the laboratory. If follow-up studies and early-phase trials bear out these findings, tepotinib’s second act may prove more consequential than its first, and LY75 may take its place among the actionable targets of precision oncology.

Microsoft’s patch for September is a doozy, with a record number of roughly 972 vulnerabilities fixed and 112 of them meeting the high critical-severity threshold.

It was only two months ago that Microsoft patched a then-record 570 vulnerabilities. Then, last month, Microsoft patched some 620 of them. Google and other companies have also published record numbers of vulnerabilities in recent months. Two weeks ago, OpenAI, Anthropic, Amazon Web Services, Google, Microsoft, and 100 companies and organizations published an open letter warning of a narrowing window for patching vulnerabilities ahead of an expected tsunami of AI-enabled attacks that actively exploit them first. The industry is taking the threat seriously by pumping out unprecedented numbers of patches in their software.

Welcome to the new normal

Dustin Childs, a researcher at the Zero Day Initiative, calls the spikes the “new normal” and also cautions that despite them, the damage that’s likely to result from AI-assisted attacks could eventually be substantial.

Read full article

Comments

Microsoft’s patch for September is a doozy, with a record number of roughly 972 vulnerabilities fixed and 112 of them meeting the high critical-severity threshold.

It was only two months ago that Microsoft patched a then-record 570 vulnerabilities. Then, last month, Microsoft patched some 620 of them. Google and other companies have also published record numbers of vulnerabilities in recent months. Two weeks ago, OpenAI, Anthropic, Amazon Web Services, Google, Microsoft, and 100 companies and organizations published an open letter warning of a narrowing window for patching vulnerabilities ahead of an expected tsunami of AI-enabled attacks that actively exploit them first. The industry is taking the threat seriously by pumping out unprecedented numbers of patches in their software.

Welcome to the new normal

Dustin Childs, a researcher at the Zero Day Initiative, calls the spikes the “new normal” and also cautions that despite them, the damage that’s likely to result from AI-assisted attacks could eventually be substantial.

Read full article

Comments

The post Researcher, heal thyself: meet the scientists studying their own diseases appeared first on MIT School of Science.

Apple Podcasts runs within CarPlay, Apple’s in-car software platform for accessing compatible iPhone apps through a vehicle’s display and controls. CarPlay provides the driving environment, while Podcasts supplies the programs, episodes, library and playback features available inside it.

That combination suits a part of the day that often feels wasted. A commute may be too fragmented for reading or watching something, but it can provide enough uninterrupted time for a news briefing, interview, documentary series or comedy show.

Podcasts also give each journey a different character. The morning drive can offer information before work, while the return trip can provide lighter entertainment or continue a longer story. Drivers are free to choose whether the time should be useful, relaxing or simply less repetitive.

Apple Podcasts Fits Naturally Inside CarPlay

Apple Podcasts appears alongside other compatible audio apps when an iPhone connects to CarPlay. The vehicle display offers access to available episodes and essential controls without reproducing the complete iPhone interface on the dashboard.

The distinction is simple: Apple Podcasts does not create or power CarPlay. It is an audio app designed to operate within the wider CarPlay experience, which also handles navigation, calls, messages and other supported services.

CarPlay reduces podcast playback to the functions most appropriate in a vehicle. Drivers can use the Now Playing screen, CarPlay Dashboard, steering-wheel controls or buttons provided by the vehicle. Available commands can include playing, pausing, jumping back 15 seconds, moving forward 30 seconds and changing playback speed.

Siri provides another way to manage audio while keeping attention on the road. A driver can request a followed show, pause the current episode or continue listening without searching through the display. Support varies according to the vehicle and its controls, but the app remains connected to the iPhone rather than operating as a separate system installed by the automaker.

The interface is especially suitable for spoken audio. Songs can often continue without intervention, while a podcast listener may want to replay an explanation, skip part of an episode or resume a program interrupted earlier. CarPlay keeps those common controls accessible without placing the full Podcasts app in front of the driver.

The Commute Becomes a Listening Window

A regular route creates a predictable amount of listening time. Someone with a 15-minute drive may prefer concise news, business updates or language lessons. A 40-minute journey provides room for detailed interviews, investigative reporting or serialized fiction.

Apple Podcasts includes programs covering education, technology, culture, history, sports, health and entertainment. The variety allows listeners to build different routines around the same drive rather than depending on one radio schedule or repeatedly hearing familiar music.

A morning episode can provide context for events likely to shape the working day. On the way home, comedy and conversational programs can create distance from work before the listener reaches the front door. Neither choice requires treating every available minute as a productivity exercise.

The format can also make traffic less frustrating. A delayed journey remains inconvenient, but an episode gives the driver something continuous to follow as the arrival time changes. Spoken stories can hold attention without asking the driver to look away from navigation or the road.

Apple Podcasts keeps longer programs useful even when they do not fit into one trip. Listening progress can synchronize across compatible devices using the same Apple Account, allowing an episode started at home to continue in the car or resume later on another device.

Preparation Makes CarPlay Listening Better

The safest podcast decision is usually the one made before the car starts moving. Apple Podcasts allows listeners to follow shows, download episodes and arrange a queue on the iPhone in advance. CarPlay can then concentrate on playback instead of discovery.

A prepared queue is useful when several episodes are planned for one journey. The next selection can begin automatically after the current program ends, removing the temptation to search through categories while driving. Listeners can combine a short briefing with a longer interview or place lighter material after a demanding program.

Downloads make the experience more reliable. Saved episodes can continue playing through areas with weak cellular coverage, including rural roads, tunnels and underground parking structures. Downloading through Wi-Fi can also prevent a long daily routine from consuming unnecessary mobile data.

Automatic downloads can keep recent episodes from followed shows ready for the next drive. Storage still requires attention, especially when subscriptions publish frequently, but played downloads can be removed automatically according to the selected Podcasts settings.

Playback speed provides another form of control. Faster playback can help a listener finish a familiar news format within a shorter trip, while normal or slower speeds may suit technical discussions, unfamiliar accents or narrative programs where delivery forms part of the experience.

Listening Continues After the Car Stops

CarPlay does not create a separate podcast library inside the vehicle. It extends the listening activity already connected to the iPhone, preserving followed shows, saved programs and playback position when the drive ends.

That continuity prevents commute listening from becoming isolated. A listener can discover and prepare episodes on an iPhone, hear part of one through CarPlay and continue later on a Mac or another compatible device. Downloads remain stored on the device that received them, while supported library information and progress can synchronize through the Apple Account.

Commute length can eventually shape a personal programming schedule. A 12-minute daily news show may fit the morning route almost exactly, while a 45-minute interview can cover both directions with the remaining section ready for the following day. The queue can change with the calendar, leaving shorter episodes for busy mornings and deeper programs for the roads that provide enough time to hear them properly.

The post Apple Podcasts Is a Perfect Match for CarPlay appeared first on AppleMagazine.

Paramount Skydance agreed to a longer-term delay of its $111 billion acquisition of Warner Bros. Discovery, preventing the companies from combining until after a judge rules on the merits of a case in which a dozen states challenged the legality of the merger.

Under a stipulation filed in court today, the states and companies agreed that the merger will not be completed and the firms will not integrate their operations until "five days after the merits determination in these matters," or on June 1, 2027, whichever is earlier. The delay was also agreed to by the Writers Guild of America, which filed its own lawsuit to block the merger. If there is no merits determination by June 1, the plaintiffs could seek a preliminary injunction to keep blocking the deal.

The agreement amounts to "a months-long halt" to the merger, New York Attorney General Letitia James' office said. “Halting this merger while our case proceeds is a critical victory in our efforts to uphold the law and protect the film and television industries," James said.

Read full article

Comments

In an era where depression remains one of the most pervasive mental health disorders worldwide, emerging research continues to unravel the complex interactions within our bodies that may offer new treatment avenues. A groundbreaking study recently published in Translational Psychiatry has illuminated a remarkable connection between the vagus nerve, gut microbiota, and the antidepressant effects of a novel compound called ineupatorolide B. This discovery not only broadens the scientific understanding of depression but also signals new directions for therapeutic interventions targeting the gut-brain axis.

Depression’s multifaceted nature has long challenged researchers and clinicians alike. Traditionally, treatments have focused on modulating neurotransmitters in the brain, such as serotonin and dopamine. However, increasing evidence reveals that the gut-brain axis — a bidirectional communication pathway linking the central nervous system and the gastrointestinal tract — plays a critical role in regulating mood and behavior. The vagus nerve acts as a central highway in this communication chain, transmitting signals between the gut microbiota and the brain. New data suggests that manipulating this neural conduit might be key to unlocking novel antidepressant mechanisms.

At the core of the study by Wang and colleagues lies ineupatorolide B, a bioactive compound isolated from natural sources with previously unexplored neuropsychiatric potential. Using a well-validated mouse model of depression, the researchers meticulously demonstrated that administration of ineupatorolide B amends depressive-like behaviors, an effect intricately linked to alterations in the gut microbial community. The compound’s antidepressant actions were shown to be dependent on an intact vagus nerve, underscoring the impossibility of fully dissociating gut-brain interactions from mood regulation.

To induce depressive symptoms in mice, the team employed chronic stress paradigms mimicking real-world psychological stressors. Behavioral assessments post-treatment revealed notable improvements in exploratory behavior and reduced signs of despair, pointing to the efficacy of ineupatorolide B. Subsequent gut microbiota analyses uncovered a significant shift in microbial diversity and composition following treatment, characterized by an enrichment of beneficial bacterial taxa previously associated with anti-inflammatory and neuroprotective functions.

The vagus nerve, often described as the “information superhighway” of the parasympathetic nervous system, emerged as the linchpin in this neuro-gastrointestinal axis. When the researchers surgically severed or pharmacologically inhibited the vagus nerve, the antidepressant benefits of ineupatorolide B were abolished. This pivotal finding confirms that gut microbiota alterations alone are insufficient and must be coupled with vagus-mediated signaling to exert mood-enhancing effects, highlighting a complex neuroimmune dialogue.

Delving deeper, molecular and immunohistochemical analyses revealed that ineupatorolide B impacts systemic and neural inflammatory pathways. The compound reduced expression of pro-inflammatory cytokines within the hippocampus, a brain region critically implicated in mood disorders, while simultaneously fostering neurogenesis and synaptic plasticity. These neurobiological enhancements offer plausible mechanistic explanations for the behavioral improvements observed and reinforce the notion that inflammation is intricately tied to depression’s pathophysiology.

Perhaps most intriguingly, the study unveiled a specific pattern of microbial metabolites altered by ineupatorolide B treatment. These metabolites are hypothesized to cross the gut-blood barrier and act on vagal afferent fibers, modulating neuronal excitability and neurotransmitter release. Such findings cultivate an emerging paradigm where microbial metabolites are not mere byproducts but active signaling molecules intricately shaping the neurochemical milieu of the brain.

The implications of these findings ripple far beyond basic science. In clinical settings, harnessing vagus-dependent pathways could revolutionize antidepressant therapies by focusing on microbiota modulation rather than conventional neurotransmitter-targeted drugs, many of which suffer from delayed onset and limited efficacy. This research provides a compelling preclinical rationale for developing compounds that modulate gut-brain interactions more precisely and with fewer adverse effects.

Moreover, the identification of ineupatorolide B as a bioactive agent extends the possibilities of phytochemical and natural product libraries as untapped reservoirs for neuropsychiatric drug discovery. While still in early stages, translational efforts can now investigate whether such compounds, alone or in synergy with probiotic treatments, can elicit robust therapeutic outcomes in humans suffering from depression and related disorders.

Future inquiries will need to delineate the precise molecular receptors on vagal afferents activated by microbial metabolites induced by ineupatorolide B, a vital step toward targeted drug design. Additionally, unraveling the longitudinal effects and safety profiles of modulating the gut-brain axis via this compound will be essential in moving toward clinical applications.

Beyond depression, these insights may have broader implications for other neuropsychiatric and neurodegenerative diseases also characterized by gut dysbiosis and neuroinflammation, such as anxiety, Parkinson’s disease, and multiple sclerosis. As the field of psychobiotics burgeons, the vagus nerve stands out as a promising therapeutic target whose modulation could recalibrate the neural circuits governing emotion, cognition, and behavior.

The integration of microbiology, neurobiology, and pharmacology showcased in this study epitomizes the power of interdisciplinary science to unlock novel therapeutic pathways. Wang and colleagues’ work thus represents a beacon in personalized medicine strategies aimed at mental health, a field urgently craving innovation as global depression rates continue to climb amid societal challenges.

In summary, the discovery that ineupatorolide B’s antidepressant efficacy is mediated by vagus nerve-dependent modulation of gut microbiota ushers in a transformative perspective on depression treatment. By bridging peripheral microbial ecosystems with central nervous system function via neural pathways, this research redefines our understanding of depression’s origins and therapeutic targets, inspiring the next generation of holistic and targeted interventions for mental health.

As the scientific community rallies around the gut-brain axis, studies such as this underscore the necessity of viewing depression through a systemic lens, acknowledging the profound interplay between the body and mind. This conceptual shift stands poised to not only improve treatment outcomes but also destigmatize mental illness by emphasizing its biological complexity.

Ultimately, as neuroscience continues to unravel the enigmatic connections between microbiota, neural circuits, and behavior, hopes rise for innovative treatments grounded in nature’s own chemical repertoire. Ineupatorolide B shines as a fascinating candidate at this frontier, exemplifying the promise held by gut-mediated neuromodulation in conquering depression’s global burden.

Subject of Research:
Vagus nerve-mediated antidepressant effects of ineupatorolide B through modulation of gut microbiota in a mouse depression model.

Article Title:
Vagus nerve–dependent antidepressant effects of ineupatorolide B via gut microbiota modulation in a mouse model of depression.

Article References:
Wang, S., Zhang, Y., Wu, N. et al. Vagus nerve–dependent antidepressant effects of ineupatorolide B via gut microbiota modulation in a mouse model of depression. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04127-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04127-x

In a groundbreaking series of experiments conducted by researchers at the University of Jena, scientists have revisited and expanded upon a century-old discovery that shapes our understanding of embryonic development. Originally unearthed by Hans Spemann and his student Hilde Mangold in 1924, the concept of the “organiser” is a pivotal developmental mechanism that directs the formation of body axes during the early stages of an embryo’s growth. Spemann and Mangold’s pioneering work involved tissue transplantation between amphibian embryos, revealing the presence of a group of cells within the blastopore that orchestrate the development of a secondary body axis. This discovery earned Spemann a Nobel Prize in 1935 but tragically Mangold passed away young, never witnessing the lasting impact of their findings.

The new research from Jena not only reaffirms these foundational insights but extends them dramatically into the early evolutionary origins of metazoans. Using delicate microsurgical manipulation, the team studied the ribbed comb jelly Mnemiopsis leidyi, a member of the ancient phylum Ctenophora. This lineage diverged from that of other animals approximately 700 million years ago, according to the latest evolutionary models. By transplanting small portions of blastoporal tissue from one comb jelly embryo into another, Jena researchers induced a secondary body axis, effectively recapitulating Spemann and Mangold’s classic findings but now in one of the earliest-diverging animal lineages. The experiment demonstrated that the organiser’s developmental blueprint is deeply conserved across vast evolutionary time frames.

What makes these experiments particularly astounding is the technical difficulty involved. Comb jelly embryos measure only about 120 micrometers in diameter—just a fraction larger than the width of a human hair—while the transplanted tissue samples were barely 20 micrometers in size. Dr. Stanislav Kremnyov, the lead experimentalist, had to master an extraordinary level of manual dexterity to integrate these tiny groups of cells into host embryos without triggering rejection or other developmental derailments. To an outside observer, it appeared as if the researchers were “dissecting clouds,” a vivid metaphor used by Prof. Andreas Hejnol, who leads the research team at Jena.

The functional transplantation of organising tissue between individuals of the same species was spectacular enough. Yet the Jena team dared to push further by performing xenotransplantations, transferring organiser tissue across animal orders into the sea anemone, a cnidarian species that diverged from ctenophores roughly 60 million years later. Remarkably, the transplanted organiser tissue also initiated axis formation in the sea anemone embryos. This unprecedented success underscores the extraordinary evolutionary conservation of developmental mechanisms underpinning animal body plans. Xenotransplantation of organiser tissues across distinct phyla had never before been demonstrated, marking this as a historic advance in developmental biology.

Beyond the cellular choreography, the study also zeroed in on genetic underpinnings. The team identified, for the first time, the specific gene responsible for organiser formation in the sea anemone, bridging molecular mechanisms across species boundaries. This gene appears to regulate the signalling networks critical to early embryonic axis determination, providing a molecular anchor to the organiser’s functional role. Such findings hint that the genetic toolkit necessary for complex body plan organisation was already present in the earliest multicellular ancestors of modern animals.

These discoveries overturn previous assumptions that organiser-driven axis formation was a feature exclusive to more recently evolved animal groups such as bilaterians. Instead, the findings position the organiser as a primordial control system in multicellular organism development, dating back to the dawn of animal evolution itself. It suggests a remarkable evolutionary continuity where the fundamental blueprints for constructing the three-dimensional architecture of multicellular animals remained largely stable across hundreds of millions of years.

The implications of this research extend far beyond ctenophores and sea anemones. Since the organiser guides the spatial coordination of cell fate during development, understanding its origins and conservation sheds light on the evolutionary emergence of animal diversity and complexity. It also offers potential new perspectives for biomedical research, particularly in regenerative medicine and congenital defect studies, where guiding axis formation and tissue patterning is critical.

Technical mastery was central to these findings. The researchers employed advanced microscopy and vital cell staining techniques allowing them to trace transplanted cells dynamically within host embryos. Coupling this with precise microsurgical transplantation provided not only functional but also visual confirmation of organiser activity. This combination of cutting-edge experimental methods enabled insights previously thought unattainable in such fragile and inaccessible embryonic systems.

Prof. Andreas Hejnol reflects on the evolutionary significance with enthusiasm: “Our data demonstrate that this organizer mechanism coordinates the entire body axis and is conserved among one of the earliest-diverging animal lineages, suggesting that complex body plan organisation arose very early in metazoan evolution.” His team’s work bridges developmental biology with evolutionary biology, providing a vivid example of how ancient developmental principles underpin the incredible diversity of life forms on Earth today.

This research, published in the prestigious journal Nature, represents a milestone in understanding early animal evolution and embryogenesis. It dramatically shifts the paradigm surrounding the origins of the organiser and prompts reconsideration of the molecular and cellular processes foundational to animal multicellularity. As scientists continue to explore these ancient mechanisms, further revelations about the building blocks of life’s complexity are eagerly anticipated.

Subject of Research: Animals
Article Title: A blastoporal organiser in a ctenophore
News Publication Date: 17-Jun-2026
Web References: http://dx.doi.org/10.1038/s41586-026-10643-z
Image Credits: Lisa-Marie Barf
Keywords: embryonic development, organiser, blastopore, ctenophore, Mnemiopsis leidyi, evolutionary biology, axis formation, multicellularity, xenotransplantation, sea anemone, cnidaria, developmental genetics

A groundbreaking discovery has emerged from the subtropical mangrove wetlands of Hengqin Island, Guangdong Province, where a team of researchers from Sun Yat-sen University, in collaboration with other institutions, has identified a new species of bumblebee goby, Brachygobius jennie. This finding not only extends the known geographical distribution of the genus Brachygobius northeastward but also documents the first recorded presence of this group of small, estuarine fishes in China. The discovery was published in the prestigious journal Zoosystematics and Evolution, shedding light on a species that challenges conventional understanding of biodiversity in well-studied regions.

During routine fieldwork in the Zhujiang River Estuary wetlands, Jiangyan Tian, a postgraduate student at SYSU, was captivated by the presence of diminutive fishes inhabiting shallow waters near the substrate. Initially mistaken for juveniles of known species, these tiny organisms intrigued Tian due to their distinctive body markings, which deviated from any documented regional fish species. This unexpected observation prompted a deep dive into integrative taxonomic methods that combined morphological examination with genetic analyses, facilitated by her supervisor Jianrong Huang and colleagues Chunliu Lan and Jianyong Wu.

The integration of genetic sequencing and morphological diagnostics was pivotal in delineating Brachygobius jennie as a novel species. The comprehensive study leveraged molecular phylogenetics to affirm the genetic distinctiveness of the new goby relative to its congeners. Morphologically, B. jennie displays a unique pattern of four narrow body bars located behind the head, a trait not observed in related species. Notably, the presence of a chevron-shaped second bar that extends fully to the midventral line provides a striking visual marker distinguishing this species, alongside two additional bars positioned posterior to the anal fin base.

This species’ extraordinary small stature sets it apart within its genus and the broader ichthyofauna of China. Reaching a maximum standard length of under nine millimeters, Brachygobius jennie may be the smallest fish species known in China, and among the tiniest vertebrates worldwide. Such extreme miniaturization necessitates profound anatomical and physiological adaptations, which remain fertile ground for future biological investigation. These evolutionary modifications induced by size constraints offer critical insight into developmental biology and ecological specialization within aquatic vertebrates.

Co-author Sébastien Lavoué from Universiti Sains Malaysia expressed enthusiasm for the collaboration, highlighting the novelty and distinctiveness of Brachygobius jennie. His involvement underscores the international scientific interest in this diminutive and unique goby, bridging expertise across countries and disciplines. The interdisciplinary approach adopted by the research team exemplifies modern taxonomy’s reliance on cross-border cooperation and advanced methodologies, crucial for uncovering concealed biodiversity even in well-explored ecosystems.

The nomenclature of this newly described species holds particular cultural significance. The fish is named in honor of Jennie Ruby Jane, a prominent South Korean singer, whose music served as a beacon of inspiration for Jiangyan Tian during the demanding phases of the research. This homage illustrates the interplay between science and personal experience, enriching the narrative of scientific discovery by acknowledging influences beyond the laboratory or field site.

Brachygobius jennie inhabits estuarine environments characterized by subtropical mangrove wetlands, a habitat typified by dynamic salinity gradients, rich organic substrates, and ecological complexity. These environments are increasingly under anthropogenic threat from urbanization, pollution, and climate change, putting endemic and specialized species at risk. The identification of B. jennie brings attention to the biodiversity value of estuarine ecosystems in Asia, which remain insufficiently described and often overlooked in conservation planning, despite their ecological significance.

The discovery also contributes fundamentally to ichthyology by exemplifying how miniaturized vertebrates negotiate constraints imposed by limited body size. These fishes exhibit adaptations in skeletal morphology, sensory systems, and reproductive strategies that infer evolutionary trade-offs and developmental constraints relevant to vertebrate biology at large. As such, Brachygobius jennie represents a valuable model organism for future studies aiming to unravel these complex biological phenomena.

This finding challenges the assumption that the fish fauna of the Zhujiang River Estuary is exhaustively cataloged. Instead, it reveals that even in relatively well-studied geographic regions, cryptic biodiversity continues to exist, underscoring the infinite complexity and richness of aquatic life. It advocates for continuous exploration and integrative taxonomic research employing advanced tools like molecular genetics to unmask hidden species diversity.

Moreover, the use of integrated genetic and morphological approaches exemplifies modern taxonomic standards, enhancing the accuracy and robustness of species identification. This comprehensive methodology is essential for avoiding taxonomic ambiguities and misidentifications, which can have far-reaching implications for biodiversity assessment, ecological research, and conservation strategies focused on protecting vulnerable taxa and their habitats.

Brachygobius jennie’s diminutiveness invites biologists to probe evolutionary scenarios of size reduction among fishes, including mechanisms such as heterochrony, paedomorphosis, and resource-driven selective pressures. Examining how these tiny organisms maintain viability and reproductive success could uncover key insights into vertebrate life history evolution, with potential applications extending beyond ichthyology into broader evolutionary and developmental biology fields.

In conclusion, the discovery of Brachygobius jennie advances the scientific community’s understanding of fish diversity, biogeography, and evolutionary biology. It also emphasizes the enduring value of meticulous fieldwork, integrative taxonomy, and interdisciplinary collaboration for uncovering the hidden facets of biodiversity. As environmental threats loom over estuarine ecosystems globally, such findings highlight the urgency of documenting and conserving even the smallest and least conspicuous of species, which may hold profound biological and ecological importance.

Subject of Research: Animals

Article Title: Brachygobius jennie, a new bumblebee goby (Teleostei, Oxudercidae) from Hengqin Island, Guangdong Province, China

News Publication Date: 17-Jun-2026

Web References:
http://dx.doi.org/10.3897/zse.102.184142

Image Credits: Jiangyan Tian et al. (2026)

Keywords: Brachygobius jennie, Bumblebee goby, New species, Extreme miniaturization, Estuarine fish, Molecular phylogenetics, Morphology, Guangdong Province, Hengqin Island, Ichthyology, Biodiversity, Mangrove wetlands

Paramount Skydance is accusing Netflix of maintaining a campaign against its proposed acquisition of Warner Bros. Discovery (WBD).

In a June 5 letter (PDF) addressed to Jared A. Hughes, acting section chief of the Media, Entertainment, and Communications Section of the US Department of Justice's (DOJ's) Antitrust Division, and A. Maya Kahn, a trial attorney for the Antitrust Division, and first reported on by Politico today, Paramount chief legal officer Makan Delrahim accused Netflix of trying to influence stakeholders about the merger. The letter reads:

Indeed, Netflix’s panic-level response and scorched-earth campaign to try and poison regulators and other stakeholders against the Transaction shows just how seriously Netflix takes Paramount as a scaled competitor.

The letter from Delrahim, a former assistant attorney general for the Antitrust Division, is a response to a letter that The International Brotherhood of Teamsters sent to the DOJ in March. The teamsters' letter argued that Paramount and WBD's merger would threaten film and TV workers. The union, which has 1.3 million members, asked the DOJ to block the merger "unless substantial and enforceable safeguards are put in place to increase domestic production and protect jobs," per an announcement from the group.

Read full article

Comments

While searching for new Higgs bosons the CMS experiment at the Large Hadron Collider (LHC) may have just found a surprise. They have observed an excess of events that look to be a new particle, and are reporting high statistical evidence for their claim. The only question is what exactly is this new particle?

The search was initially designed to look for new, heavier, versions of the Higgs boson decaying to a top quark and an anti-top quark. Its well known that the Higgs boson of the Standard Model, discovered jointly by ATLAS and CMS in 2012, underlies the mechanism which gives all fundamental particles their masses. The Higgs boson itself interacts with particles in proportion to their mass, preferring heavier particles over lighter ones. It therefore interacts the most strongly with the heaviest known fundamental particle, the top quark, which has a mass of ~173 GeV. The Higgs boson itself only has a bass of 125 GeV, meaning conservation of energy dictates it can’t decay into a top quark-antiquark pair.

However many theories of physics beyond the the Standard Model predict additional Higgs bosons, heavier cousins of the current one. If these new heavy Higgs bosons had a mass larger than 350 GeV, they would likely decay to a top quark-antiquark pair quite often. CMS therefore was analyzed its data searching for this signature, hoping to find signs of a new Higgs boson. To do so, they had scrutinize very carefully the known production of top quark-antiquark pairs, which are produced copiously at the LHC from other processes. If a new particle was being produced and decaying to top quarks, the mass of the new particle would give the top quarks a characteristic energy. One key sign of a new particle would therefore be an excess of top quark-antiquark events at a particular energy, corresponding to the mass of the new particle. 

When CMS scrutinized their data looking for such an excess they found one. But curiously right ~350 GeV, the minimum energy required to produce the top quark-antiquark pair. It would be quite the coincidence for a new particle to show up right at this minimum threshold, which made CMS consider alternative possibilities.

 

 One unorthodox explanation that seems to fit the bill is ‘toponium’, a short lived bound state of the top quark-antiquark pair is being formed. Toponium would be the heaviest version of ‘quarkonia’ we have seen, bound states of quark antiquark pairs that form bound states similar to atoms. We have observed and measured quarkonia states of the other quarks for decades, however it was long thought that the top quark, whose large mass causes it to decay in just 10^(-25) seconds, would decay too quickly to create observable bound state effects at a hadron collider. Toponium production would happen most often if the top quarks were produced just at the energy threshold, such that they don’t any extra energy. These low energy top quarks would spend more time close to each other than normal, rather than immediately flying away, so they could have time to briefly form a toponium state before decaying. However, once small hints of intriguing excesses started appearing in LHC analyses, updated calculations in the last few years suggested that perhaps such an effect could be observable.

These calculations are approximate, and more work is still being done to refine them. But the preliminary predictions they give for the properties of toponium seem to match well with what CMS is seeing, both in terms of the rate of toponium production and the quantum properties of the toponium state (spin and parity).

Still CMS is being cautious before claiming a discovery of toponium. They claim observation of an ‘excess at the top quark pair production threshold’ which is consistent with toponium. However given the limited present data and incomplete theoretical models of toponium, they cannot rule out that the excess they are seeing is coming from a new Higgs-like particle.

Further work will be needed to develop improved theoretical models of toponium, and detailed studies from CMS assessing the properties of their observed excess. The excess will also need confirmation from CMS’s rival LHC experiment, ATLAS, to ensure it has not merely made a mistake in its analysis.

However, the smart money would say this very likely looks like toponium. Which, while not signaling the long sought overthrow of the standard model, would be an unexpected and cool surprise from the LHC. Understanding the properties of this previously-thought-impossible quasiparticle will spawn much fruitful research in the years to come. Physicists love a surprise!

Paper:

“Observation of a pseudoscalar excess at the top quark pair production threshold” https://arxiv.org/abs/2503.22382

Additional CMS Paper considering Heavy-Higgs interpretation “Search for heavy pseudoscalar and scalar bosons decaying to top quark pairs in proton-proton collisions”

Read more

CERN Courier “CMS observes top–antitop excess“

Symmetry Magazine “Don’t call it toponium“

Discloure: The author is a member of the CMS collaboration but did not directly work on this analysis

Erratum 4/15/2025 : The article was updated to clarify that in the theory literature prior to the LHC toponium was thought possible to form, just that it was thought to be too small an effect to be observable. The article previously incorrectly stated it had been previously thought impossible to form